Compare Biogen Inc (BIIB) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs ProShares Ultra QQQ ETF — how do they compare? Biogen Inc trades at $195.89 (market cap $28.34B), while ProShares Ultra QQQ ETF trades at $91.06. Which is the better fit depends on your goals.
| BIIB | QLD | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.63 | $100.53 |
52-Week Low | $122.68 | $57.16 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
QLD, the ProShares Ultra QQQ ETF, trades at $90.13, down 3.81% over 24 hours, reflecting a bearish technical signal with key support at $87. As a 2x daily leveraged ETF tracking the Nasdaq-100, it offers amplified exposure to large-cap tech stocks but carries inherent volatility risks. Recent news highlights its long-term performance, with over 10,000% total return since inception, though comparisons with 3x leveraged alternatives underscore drawdown vulnerabilities.
The outlook for QLD hinges on Nasdaq-100 momentum, with tech earnings and AI optimism as potential catalysts. However, leveraged decay and market volatility pose significant risks, making it suitable only for tactical, risk-tolerant investors. Current neutral oscillators suggest near-term consolidation, but bearish moving averages indicate downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
